The immunomodulatory capacity of mesenchymal stem cells

Trends in Molecular Medicine

Volumn 18, Issue 2, 2012, Pages 128-134

  Gebler, Antje ^a   Zabel, Olivia ^a   Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; B7 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD45 ANTIGEN; CD79A ANTIGEN; CD86 ANTIGEN; COMPLEMENTARY DNA; ENDOGLIN; HERMES ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MICROSOMAL AMINOPEPTIDASE; PROSTAGLANDIN E2; STROMAL CELL DERIVED FACTOR 1; THY 1 ANTIGEN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNINDEXED DRUG;

ADIPOCYTE; B LYMPHOCYTE; CARTILAGE CELL; CELL SUBPOPULATION; CYTOKINE PRODUCTION; HEMATOPOIETIC STEM CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NERVE CELL; OSTEOCYTE; PLASTICITY; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE;

ANIMALS; B7 ANTIGENS; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS;

EID: 84856630796     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.10.004     Document Type: Review

References (61)

1. Reyes M., et al. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 2002, 109:337-346.
2. Woodbury D., et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res. 2000, 61:364-370.
3. Sato T., et al. Impairment of cardiomyogenesis in embryonic stem cells lacking scaffold protein JSAP1. Biochem. Biophys. Res. Commun. 2005, 338:1152-1157.
4. Greco S., et al. Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. Front Biosci. 2004, 9:1782-1793.
5. Augello A., et al. Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. Eur. Cell Mater. 2010, 20:121-133.
6. Dominici M., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
7. Bassi E., et al. Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand?. World J. Stem Cells 2011, 3:1-8.
8. Traktuev D., et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ. Res. 2008, 102:77-85.
9. Bae S., et al. Combined omics analysis identifies transmembrane 4 L6 family member 1 as a surface protein marker specific to human mesenchymal stem cells. Stem Cells Dev. 2011, 20:197-203.
10. Götherström C., et al. Difference in gene expression between human fetal liver und adult bone marrow mesenchymal stem cells. Haematologica 2005, 90:1017.
11. Roche S., et al. Comparative proteomic analysis of human mesenchymal and embryonic stem cells: towards the definition of a mesenchymal stem cell proteomic signature. Neoplasma 2009, 56:331-334.
12. Dai L., et al. Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett. 2011, 305:8-20.
13. Shi M., et al. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin. Exp. Immunol. 2011, 164:1-8.
14. Smith H., et al. Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells Dev. 2011 June 15.
15. Singer N.G., Caplan A.I. Mesenchymal stem cells: mechanisms of inflammation. Annu. Rev. Pathol. 2011, 6:457-478.
16. da Silva Meirelles L., et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009, 20:419-427.
17. Mielcarek M., et al. Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation. Biol. Blood Marrow Transplant. 2011, 17:214-225.
18. Morandi F., et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (Dayton, Ohio) 2008, 26:1275-1287.
19. Le Blanc K., et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 2003, 57:11-20.
20. Rasmusson I., et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
21. Deans R., Moseley A. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 2000, 28:875-884.
22. Pittenger M., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
23. Chamberlain G., et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells (Dayton, Ohio) 2007, 25:2739-2749.
24. DelaRosa O., Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediators Inflamm. 2010, 2010:865601.
25. Sato K., et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
26. Augello A., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 2005, 35:1482-1490.
27. Maccario R., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90:516-525.
28. Sensebé L., et al. Mesenchymal stem cells for clinical application. Vox Sang. 2010, 98:93-107.
29. Ivanova-Todorova E., et al. HLA-G expression is up-regulated by progesterone in mesenchymal stem cells. Am. J. Reprod. Immunol. 2009, 62:25-33.
30. Le Blanc K., et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 2003, 31:890-896.
31. - progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but no CXCR4. Stem Cells Dev. 2005, 14:329-336.
32. da Silva Meirelles L., et al. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299.
33. Aggarwal S.P., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
34. Han K., et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transpl. Immunol. 2011, 25:7-15.
35. Corcione A., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
36. Nauta A., et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 2006, 177:2080-2087.
37. Spaggiari G., et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111:1327-1333.
38. Spaggiari G.M., et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
39. Zhang W., et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004, 13:263-271.
40. Prigione I., et al. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 2009, 27:693-702.
41. Devine S., et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003, 101:2999-3001.
42. Nasef A., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84:231-237.
43. Bernardo M., et al. Mesenchymal stromal cells. Ann. N. Y. Acad. Sci. 2009, 1176:101-117.
44. Krampera M., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24:386-398.
45. Sotiropoulou P., et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24:74-85.
46. Tuettenberg A., et al. Immune regulation by dendritic cells and T cells - basic science, diagnostic, and clinical application. Clin. Lab. 2011, 57:1-12.
47. Caimi P.F., et al. Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Curr. Opin. Hematol. 2010, 17:505-513.
48. Garcia-Gomez I., et al. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin. Biol. Ther. 2011, 10:1453-1468.
49. Sato K., et al. Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes. J. Clin. Exp. Hematop. 2010, 50:79-89.
50. Tolar J., et al. Concise review: hitting the right spot with mesenchymal stromal cells. Stem cells (Dayton, Ohio) 2011, 28:1446-1455.
51. Macdonald G.I., et al. Mesenchymal stem cells: re-establishing immunological tolerance in autoimmune rheumatic diseases. Arthritis Rheum. 2011, 63:2547-2557.
52. Tyndall A., Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant. 2009, 43:821-828.
53. Maumus M., et al. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res. Ther. 2011, 2:14.
54. Price S. Experimental arthritis: dermal fibroblasts have MSC-like immunosuppressive effects in vivo. Nat. Rev. Rheum. 2011, 7:437.
55. Weil B.R., et al. Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery 2010, 148:444-452.
56. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp. Hematol. 2009, 37:1445-1453.
57. Lee J.W., et al. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin. Biol. Ther. 2009, 9:1259-1270.
58. Vija L., et al. Mesenchymal stem cells: stem cell therapy perspectives for type 1 diabetes. Diabetes Metab. 2009, 35:85-93.
59. Del Papa N., et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006, 54:2605-2615.
60. Rubio D., et al. Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS ONE 2008, 3:e1398.
61. Sudres M., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 2006, 176:7761-7767.